Ciltistotug

希替苏塔单抗

Report date: 2025/11/10 15:47:19

Base Information

Drug NameCiltistotug
Drug Alias NameYH-003YH003
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionTumor necrosis factor receptor superfamily member 5 agonists
TargetsTumor necrosis factor receptor superfamily member 5
Therapy Area/IndicationsSolid tumoursPancreatic NeoplasmsCarcinoma, Pancreatic Ductal +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanNew Zealand +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesEucure Pharmaceutical Technology (Beijing) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesIsu Abxis Co LtdBiocytogen Pharmaceuticals (Beijing) Co LtdEucure Pharmaceutical Technology (Beijing) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursPancreatic NeoplasmsCarcinoma, Pancreatic Ductal +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A